Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Mar;38(3):611–615. doi: 10.1128/aac.38.3.611

Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.

V Korten 1, J F Tomayko 1, B E Murray 1
PMCID: PMC284507  PMID: 8203863

Abstract

The in vitro activity of DU-6859a (DU), a new fluoroquinolone agent, was evaluated against 233 gram-positive cocci and was compared with those of ciprofloxacin, vancomycin, nafcillin, and ampicillin. The MICs of DU for 90% of the staphylococci tested were < or = 0.06 microgram/ml. All of the groups A and B and viridans group streptococci were inhibited by < or = 0.125 microgram of DU per ml, which was 32-fold more active than ciprofloxacin. On the basis of MICs for 90% of the strains tested, DU was 32- and 16-fold more active than ciprofloxacin against Enterococcus faecalis and Enterococcus faecium, respectively. The bactericidal activity of DU was demonstrated by time-kill techniques against all ciprofloxacin-susceptible enterococci. DU shows promise for the treatment of infections with gram-positive cocci and warrants further evaluation by in vitro and in vivo studies.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Fuchs P. C. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991 May;35(5):955–960. doi: 10.1128/aac.35.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blumberg H. M., Rimland D., Carroll D. J., Terry P., Wachsmuth I. K. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991 Jun;163(6):1279–1285. doi: 10.1093/infdis/163.6.1279. [DOI] [PubMed] [Google Scholar]
  3. Cantón E., Pemán J., Jimenez M. T., Ramón M. S., Gobernado M. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother. 1992 Mar;36(3):558–565. doi: 10.1128/aac.36.3.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen M. A., Griffin T. J., Bien P. A., Heifetz C. L., Domagala J. M. In vitro activity of CI-934, a quinolone carboxylic acid active against gram-positive and -negative bacteria. Antimicrob Agents Chemother. 1985 Dec;28(6):766–772. doi: 10.1128/aac.28.6.766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Heifetz C. L. In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):245–258. doi: 10.1016/0732-8893(91)90039-i. [DOI] [PubMed] [Google Scholar]
  6. Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eliopoulos G. M., Klimm K., Rice L. B., Ferraro M. J., Moellering R. C., Jr Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother. 1990 Jun;34(6):1154–1159. doi: 10.1128/aac.34.6.1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fernandez-Guerrero M., Rouse M. S., Henry N. K., Geraci J. E., Wilson W. R. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis. Antimicrob Agents Chemother. 1987 Mar;31(3):430–433. doi: 10.1128/aac.31.3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fuchs P. C., Barry A. L., Pfaller M. A., Allen S. D., Gerlach E. H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991 Apr;35(4):764–766. doi: 10.1128/aac.35.4.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fukuoka Y., Ikeda Y., Yamashiro Y., Takahata M., Todo Y., Narita H. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother. 1993 Mar;37(3):384–392. doi: 10.1128/aac.37.3.384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gargallo-Viola D., Esteve M., Llovera S., Roca X., Guinea J. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob Agents Chemother. 1991 Mar;35(3):442–447. doi: 10.1128/aac.35.3.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Handwerger S., Raucher B., Altarac D., Monka J., Marchione S., Singh K. V., Murray B. E., Wolff J., Walters B. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis. 1993 Jun;16(6):750–755. doi: 10.1093/clind/16.6.750. [DOI] [PubMed] [Google Scholar]
  13. Hosaka M., Yasue T., Fukuda H., Tomizawa H., Aoyama H., Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother. 1992 Oct;36(10):2108–2117. doi: 10.1128/aac.36.10.2108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Imada T., Miyazaki S., Nishida M., Yamaguchi K., Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrob Agents Chemother. 1992 Mar;36(3):573–579. doi: 10.1128/aac.36.3.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jones R. N., Barry A. L. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 1990 Feb;34(2):306–313. doi: 10.1128/aac.34.2.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jones R. N., Erwin M. E. In vitro activity of CP-74667 compared with four other fluoroquinolones. Diagn Microbiol Infect Dis. 1992 Aug;15(6):531–536. doi: 10.1016/0732-8893(92)90104-2. [DOI] [PubMed] [Google Scholar]
  17. Kaatz G. W., Seo S. M. WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens. Antimicrob Agents Chemother. 1990 Jul;34(7):1376–1380. doi: 10.1128/aac.34.7.1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lewin C. S., Morrissey I., Smith J. T. The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis. J Pharm Pharmacol. 1991 Jul;43(7):492–494. doi: 10.1111/j.2042-7158.1991.tb03520.x. [DOI] [PubMed] [Google Scholar]
  19. Miranda A. G., Singh K. V., Murray B. E. DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool. J Clin Microbiol. 1991 Dec;29(12):2752–2757. doi: 10.1128/jcm.29.12.2752-2757.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Miranda A. G., Wanger A. R., Singh K. V., Murray B. E. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992 Jun;36(6):1325–1328. doi: 10.1128/aac.36.6.1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Murray B. E., Singh K. V., Heath J. D., Sharma B. R., Weinstock G. M. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J Clin Microbiol. 1990 Sep;28(9):2059–2063. doi: 10.1128/jcm.28.9.2059-2063.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Murray B. E., Singh K. V., Markowitz S. M., Lopardo H. A., Patterson J. E., Zervos M. J., Rubeglio E., Eliopoulos G. M., Rice L. B., Goldstein F. W. Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis. 1991 Apr;163(4):780–785. doi: 10.1093/infdis/163.4.780. [DOI] [PubMed] [Google Scholar]
  23. Sahm D. F., Koburov G. T. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother. 1989 Jan;33(1):71–77. doi: 10.1128/aac.33.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sato K., Hoshino K., Tanaka M., Hayakawa I., Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992 Jul;36(7):1491–1498. doi: 10.1128/aac.36.7.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schaberg D. R., Dillon W. I., Terpenning M. S., Robinson K. A., Bradley S. F., Kauffman C. A. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2533–2535. doi: 10.1128/aac.36.11.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Smith S. M., Eng R. H. Interaction of ciprofloxacin with ampicillin and vancomycin for Streptococcus faecalis. Diagn Microbiol Infect Dis. 1988 Apr;9(4):239–243. doi: 10.1016/0732-8893(88)90115-0. [DOI] [PubMed] [Google Scholar]
  27. Stratton C. W., Liu C., Ratner H. B., Weeks L. S. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother. 1987 Jul;31(7):1014–1016. doi: 10.1128/aac.31.7.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES